Skip to Main Content

Advertisement

Skip Nav Destination

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

Blood (2022) 140 (16): 1753–1763.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement